Thus, future studies leveraging animal models, multi-omics technologies to elucidate cellular and molecular network mechanisms of GLP-1 based T2DM therapies will undoubtedly advance personalized precision medicine for T2DM. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.